Tissue | Expression Dynamics | Abbreviation |
Cervix | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Cervix/KIF13A_pca_on_diff_genes.png) | CC: Cervix cancer |
HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions |
N_HPV: HPV-infected normal cervix |
Colorectum (GSE201348) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Becker/KIF13A_pca_on_diff_genes.png) | FAP: Familial adenomatous polyposis |
CRC: Colorectal cancer |
Colorectum (HTA11) | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Colorectum/Chen/KIF13A_pca_on_diff_genes.png) | AD: Adenomas |
SER: Sessile serrated lesions |
MSI-H: Microsatellite-high colorectal cancer |
MSS: Microsatellite stable colorectal cancer |
Esophagus | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Esophagus/KIF13A_pca_on_diff_genes.png) | ESCC: Esophageal squamous cell carcinoma |
HGIN: High-grade intraepithelial neoplasias |
LGIN: Low-grade intraepithelial neoplasias |
Liver | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Liver/KIF13A_pca_on_diff_genes.png) | HCC: Hepatocellular carcinoma |
NAFLD: Non-alcoholic fatty liver disease |
Lung | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Lung/KIF13A_pca_on_diff_genes.png) | AAH: Atypical adenomatous hyperplasia |
AIS: Adenocarcinoma in situ |
IAC: Invasive lung adenocarcinoma |
MIA: Minimally invasive adenocarcinoma |
Oral Cavity | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/OralCavity/KIF13A_pca_on_diff_genes.png) | EOLP: Erosive Oral lichen planus |
LP: leukoplakia |
NEOLP: Non-erosive oral lichen planus |
OSCC: Oral squamous cell carcinoma |
Prostate | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Prostate/KIF13A_pca_on_diff_genes.png) | BPH: Benign Prostatic Hyperplasia |
Skin | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Skin/KIF13A_pca_on_diff_genes.png) | AK: Actinic keratosis |
cSCC: Cutaneous squamous cell carcinoma |
SCCIS:squamous cell carcinoma in situ |
Thyroid | ![The image shows the transcriptomic changes along malignancy continuum.log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.](images/deg_images/Thyroid/KIF13A_pca_on_diff_genes.png) | ATC: Anaplastic thyroid cancer |
HT: Hashimoto's thyroiditis |
PTC: Papillary thyroid cancer |
GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
GO:00474961 | Oral cavity | OSCC | vesicle transport along microtubule | 27/7305 | 47/18723 | 7.93e-03 | 2.90e-02 | 27 |
GO:004819322 | Oral cavity | EOLP | Golgi vesicle transport | 72/2218 | 296/18723 | 1.43e-09 | 9.55e-08 | 72 |
GO:000689222 | Oral cavity | EOLP | post-Golgi vesicle-mediated transport | 35/2218 | 104/18723 | 4.30e-09 | 2.43e-07 | 35 |
GO:001605022 | Oral cavity | EOLP | vesicle organization | 65/2218 | 300/18723 | 8.62e-07 | 2.15e-05 | 65 |
GO:000689322 | Oral cavity | EOLP | Golgi to plasma membrane transport | 20/2218 | 60/18723 | 1.03e-05 | 1.84e-04 | 20 |
GO:007265924 | Oral cavity | EOLP | protein localization to plasma membrane | 59/2218 | 284/18723 | 1.07e-05 | 1.91e-04 | 59 |
GO:199077823 | Oral cavity | EOLP | protein localization to cell periphery | 65/2218 | 333/18723 | 3.17e-05 | 4.48e-04 | 65 |
GO:005165623 | Oral cavity | EOLP | establishment of organelle localization | 73/2218 | 390/18723 | 4.59e-05 | 6.11e-04 | 73 |
GO:000703422 | Oral cavity | EOLP | vacuolar transport | 36/2218 | 157/18723 | 6.66e-05 | 8.27e-04 | 36 |
GO:003070523 | Oral cavity | EOLP | cytoskeleton-dependent intracellular transport | 42/2218 | 195/18723 | 8.11e-05 | 9.69e-04 | 42 |
GO:005165022 | Oral cavity | EOLP | establishment of vesicle localization | 35/2218 | 161/18723 | 2.54e-04 | 2.47e-03 | 35 |
GO:000704122 | Oral cavity | EOLP | lysosomal transport | 27/2218 | 114/18723 | 2.97e-04 | 2.79e-03 | 27 |
GO:005164822 | Oral cavity | EOLP | vesicle localization | 37/2218 | 177/18723 | 3.88e-04 | 3.48e-03 | 37 |
GO:004300122 | Oral cavity | EOLP | Golgi to plasma membrane protein transport | 13/2218 | 40/18723 | 4.75e-04 | 4.16e-03 | 13 |
GO:00354594 | Oral cavity | EOLP | vesicle cargo loading | 10/2218 | 27/18723 | 6.67e-04 | 5.53e-03 | 10 |
GO:001097021 | Oral cavity | EOLP | transport along microtubule | 32/2218 | 155/18723 | 1.15e-03 | 8.37e-03 | 32 |
GO:006195121 | Oral cavity | EOLP | establishment of protein localization to plasma membrane | 16/2218 | 60/18723 | 1.29e-03 | 9.18e-03 | 16 |
GO:009887622 | Oral cavity | EOLP | vesicle-mediated transport to the plasma membrane | 27/2218 | 136/18723 | 4.73e-03 | 2.54e-02 | 27 |
GO:009015022 | Oral cavity | EOLP | establishment of protein localization to membrane | 45/2218 | 260/18723 | 5.73e-03 | 2.94e-02 | 45 |
GO:00330592 | Oral cavity | EOLP | cellular pigmentation | 13/2218 | 53/18723 | 7.67e-03 | 3.66e-02 | 13 |
Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
KIF13A | SNV | Missense_Mutation | novel | c.4210N>C | p.Asp1404His | p.D1404H | Q9H1H9 | protein_coding | tolerated(0.06) | possibly_damaging(0.45) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
KIF13A | SNV | Missense_Mutation | novel | c.2327N>A | p.Arg776Gln | p.R776Q | Q9H1H9 | protein_coding | tolerated(0.06) | benign(0.385) | TCGA-5L-AAT1-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Hormone Therapy | letrozol | SD |
KIF13A | SNV | Missense_Mutation | | c.1257G>C | p.Glu419Asp | p.E419D | Q9H1H9 | protein_coding | deleterious(0.04) | benign(0.014) | TCGA-A2-A04W-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
KIF13A | SNV | Missense_Mutation | rs76740306 | c.653N>C | p.Ser218Thr | p.S218T | Q9H1H9 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-A2-A0T2-01 | Breast | breast invasive carcinoma | Female | >=65 | III/IV | Chemotherapy | xeloda | PD |
KIF13A | SNV | Missense_Mutation | | c.2915A>G | p.His972Arg | p.H972R | Q9H1H9 | protein_coding | tolerated(0.07) | benign(0) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD |
KIF13A | SNV | Missense_Mutation | novel | c.4270N>C | p.Asp1424His | p.D1424H | Q9H1H9 | protein_coding | deleterious(0.03) | possibly_damaging(0.593) | TCGA-A7-A4SA-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | doxorubicin | CR |
KIF13A | SNV | Missense_Mutation | | c.1252G>A | p.Glu418Lys | p.E418K | Q9H1H9 | protein_coding | deleterious(0) | possibly_damaging(0.574) | TCGA-A7-A56D-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Hormone Therapy | arimidex | SD |
KIF13A | SNV | Missense_Mutation | rs76740306 | c.653G>C | p.Ser218Thr | p.S218T | Q9H1H9 | protein_coding | deleterious(0.01) | probably_damaging(0.989) | TCGA-A8-A06R-01 | Breast | breast invasive carcinoma | Female | >=65 | I/II | Chemotherapy | 5-fluorouracil | CR |
KIF13A | SNV | Missense_Mutation | | c.478N>G | p.Leu160Val | p.L160V | Q9H1H9 | protein_coding | deleterious(0) | probably_damaging(1) | TCGA-AN-A0XW-01 | Breast | breast invasive carcinoma | Female | <65 | III/IV | Unknown | Unknown | SD |
KIF13A | SNV | Missense_Mutation | novel | c.4094C>T | p.Ala1365Val | p.A1365V | Q9H1H9 | protein_coding | deleterious(0.02) | possibly_damaging(0.601) | TCGA-B6-A0RM-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Unknown | Unknown | SD |